NCT04995042View on ClinicalTrials.gov

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

May 24, 2023

Study Completion Date

May 25, 2023

Conditions

Hormone Sensitive Prostate Cancer

Interventions

DRUG

SHR7280

Drug: SHR7280 All participants receive SHR7280 alone.

Trial Locations (1)

266000

The Affiliated Hospital of Qingdao University, Qingdao

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04995042 - A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer | Biotech Hunter | Biotech Hunter